Nighttime eating and breast cancer among Chinese women in Hong Kong.

Abstract:

BACKGROUND:A novel line of research suggests that eating at nighttime may have several metabolic consequences that are highly relevant to breast cancer. We investigated the association between nighttime eating habits after 10 p.m. and breast cancer in Hong Kong women. METHODS:A hospital-based case-control study was conducted during 2012-2015. A total of 922 patients with incident breast cancer (cases) and 913 hospital controls were recruited and interviewed using a standard questionnaire including information on eating behavior during both daytime and nighttime. We collected the timing, duration, types and frequencies of food intake of eating at nighttime. Odds ratios (ORs) for the risk of breast cancer in relation to nighttime eating-related variables were calculated by unconditional multivariable logistic regression. RESULTS:Eating at night after 10 pm was significantly associated with breast cancer with an adjusted OR of 1.50 (95% confidence interval (CI) 1.06-2.12, P = 0.02), and the associations were stronger in women who had the longest duration of nighttime eating (≥20 years) (adjusted OR = 2.28 (95% CI 1.13-4.61, P = 0.02) and who ate late (midnight to 2 a.m.) (adjusted OR = 2.73, 95% CI 1.01-6.99, P = 0.04). Interestingly, nighttime eating was only associated with breast cancer among women who consumed staple foods (OR = 2.16, 95% CI 1.42-3.29, P < 0.001) but not those who ate vegetables or fruits as nighttime meals. The significant association between nighttime eating and breast cancer was observed among women with body mass index (BMI) <25 (OR = 2.29, 95% CI 1.48-3.52, P < 0.001) but not among women with BMI ≥25. CONCLUSIONS:Results from this study suggest a possible association between nighttime eating behavior and breast cancer. These findings need to be confirmed by independent large studies.

journal_name

Breast Cancer Res

authors

Li M,Tse LA,Chan WC,Kwok CH,Leung SL,Wu C,Yu WC,Lee PM,Tsang KH,Law SH,Vermeulen R,Gu F,Caporaso NE,Yu IT,Wang F,Yang XR

doi

10.1186/s13058-017-0821-x

subject

Has Abstract

pub_date

2017-03-17 00:00:00

pages

31

issue

1

eissn

1465-5411

issn

1465-542X

pii

10.1186/s13058-017-0821-x

journal_volume

19

pub_type

杂志文章
  • Measuring proliferation in breast cancer: practicalities and applications.

    abstract::Various methods are available for the measurement of proliferation rates in tumours, including mitotic counts, estimation of the fraction of cells in S-phase of the cell cycle and immunohistochemistry of proliferation-associated antigens. The evidence, advantages and disadvantages for each of these methods along with ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr1618

    authors: Beresford MJ,Wilson GD,Makris A

    更新日期:2006-01-01 00:00:00

  • Estrogen and progesterone induce persistent increases in p53-dependent apoptosis and suppress mammary tumors in BALB/c-Trp53+/- mice.

    abstract:INTRODUCTION:Treatment with estrogen and progesterone (E+P) mimics the protective effect of parity on mammary tumors in rodents and depends upon the activity of p53. The following experiments tested whether exogenous E+P primes p53 to be more responsive to DNA damage and whether these pathways confer resistance to mamm...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr2094

    authors: Dunphy KA,Blackburn AC,Yan H,O'Connell LR,Jerry DJ

    更新日期:2008-01-01 00:00:00

  • The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells.

    abstract:INTRODUCTION:Microtubule-associated protein tau (MAPT) inhibits the function of taxanes and high expression of MAPT decreases the sensitivity to taxanes. The relationship between estrogen receptor (ER) and MAPT in breast cancer is unclear. In this study, we examined the correlation of MAPT expression with the sensitivi...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr2598

    authors: Ikeda H,Taira N,Hara F,Fujita T,Yamamoto H,Soh J,Toyooka S,Nogami T,Shien T,Doihara H,Miyoshi S

    更新日期:2010-01-01 00:00:00

  • Vitamin D and breast cancer: interpreting current evidence.

    abstract::Preclinical investigations and selected clinical observational studies support an association between higher vitamin D intake and 25-hydroxyvitamin D levels with lower breast cancer risk. However, the recently updated report from the Institute of Medicine concluded that, for cancer and vitamin D, the evidence was 'inc...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr2846

    authors: Chlebowski RT

    更新日期:2011-08-16 00:00:00

  • Changes in body weight and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

    abstract:BACKGROUND:Several anthropometric measures have been found to be associated with the risk of breast cancer. Current weight, body mass index, and adult weight gain appear to be predictors of postmenopausal breast cancer. These factors have been associated with a reduced risk of premenopausal breast cancer. We asked whet...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr1293

    authors: Kotsopoulos J,Olopado OI,Ghadirian P,Lubinski J,Lynch HT,Isaacs C,Weber B,Kim-Sing C,Ainsworth P,Foulkes WD,Eisen A,Sun P,Narod SA

    更新日期:2005-01-01 00:00:00

  • Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.

    abstract:BACKGROUND:The Cancer Genome Atlas analysis revealed that somatic EGFR, receptor tyrosine-protein kinase erbB-2 (ERBB2), Erb-B2 receptor tyrosine kinase 3 (ERBB3) and Erb-B2 receptor tyrosine kinase 4 (ERBB4) gene mutations (ERBB family mutations) occur alone or co-occur with somatic mutations in the gene encoding the ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,随机对照试验

    doi:10.1186/s13058-017-0883-9

    authors: Toomey S,Eustace AJ,Fay J,Sheehan KM,Carr A,Milewska M,Madden SF,Teiserskiene A,Kay EW,O'Donovan N,Gallagher W,Grogan L,Breathnach O,Walshe J,Kelly C,Moulton B,Kennedy MJ,Gullo G,Hill AD,Power C,Duke D,Hambly N

    更新日期:2017-07-27 00:00:00

  • Breast cancer in association with thyroid disorders.

    abstract:BACKGROUND:The relationship between breast cancer and thyroid diseases is controversial. Discrepant results have been reported in the literature. The incidences of autoimmune and nonautoimmune thyroid diseases were investigated in patients with breast cancer and age-matched control individuals without breast or thyroid...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr609

    authors: Turken O,NarIn Y,DemIrbas S,Onde ME,Sayan O,KandemIr EG,YaylacI M,Ozturk A

    更新日期:2003-01-01 00:00:00

  • ALK alteration is a frequent event in aggressive breast cancers.

    abstract:INTRODUCTION:Breast cancer is the most common female malignancy worldwide and, despite improvements in treatment modalities, there are increased chances of recurrence and metastasis in a substantial number of cases and it remains one of the major causes of mortality among female cancer patients. Anaplastic lymphoma kin...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-015-0610-3

    authors: Siraj AK,Beg S,Jehan Z,Prabhakaran S,Ahmed M,R Hussain A,Al-Dayel F,Tulbah A,Ajarim D,Al-Kuraya KS

    更新日期:2015-09-17 00:00:00

  • Update on the use of aromatase inhibitors in early-stage breast cancer.

    abstract::Aromatase inhibitors are currently included in the 'optimal' management of early-stage breast cancer. Uncertainty remains, however, as to the most appropriate treatment strategy, particularly for newly diagnosed women as they seek to trade off the cost, toxicities and efficacy of the treatment options. Recent publicat...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr2410

    authors: Kesisis G,Makris A,Miles D

    更新日期:2009-01-01 00:00:00

  • Estrogen regulation of mammary gland development and breast cancer: amphiregulin takes center stage.

    abstract::Estrogen-mediated proliferation is fundamental to normal mammary gland development. Recent studies have demonstrated that amphiregulin is a critical paracrine regulator of estrogen action during ductal morphogenesis. These studies implicate a critical role for amphiregulin in mammary stem cell differentiation as well ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr1740

    authors: LaMarca HL,Rosen JM

    更新日期:2007-01-01 00:00:00

  • Diffuse optical spectroscopic imaging reveals distinct early breast tumor hemodynamic responses to metronomic and maximum tolerated dose regimens.

    abstract:BACKGROUND:Breast cancer patients with early-stage disease are increasingly administered neoadjuvant chemotherapy (NAC) to downstage their tumors prior to surgery. In this setting, approximately 31% of patients fail to respond to therapy. This demonstrates the need for techniques capable of providing personalized feedb...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-020-01262-1

    authors: Tank A,Peterson HM,Pera V,Tabassum S,Leproux A,O'Sullivan T,Jones E,Cabral H,Ko N,Mehta RS,Tromberg BJ,Roblyer D

    更新日期:2020-03-13 00:00:00

  • The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology G

    abstract:INTRODUCTION:The main prognostic variables in early breast cancer are tumor size, histological grade, estrogen receptor/progesterone receptor (ER/PgR) status, number of positive nodes and human epidermal growth factor receptor 2 (HER2) status. The present study evaluated the prognostic and/or predictive value of vascul...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,随机对照试验

    doi:10.1186/bcr3354

    authors: Linardou H,Kalogeras KT,Kronenwett R,Kouvatseas G,Wirtz RM,Zagouri F,Gogas H,Christodoulou C,Koutras AK,Samantas E,Pectasides D,Bafaloukos D,Fountzilas G

    更新日期:2012-11-12 00:00:00

  • Efficient treatment of breast cancer xenografts with multifunctionalized iron oxide nanoparticles combining magnetic hyperthermia and anti-cancer drug delivery.

    abstract:INTRODUCTION:Tumor cells can effectively be killed by heat, e.g. by using magnetic hyperthermia. The main challenge in the field, however, is the generation of therapeutic temperatures selectively in the whole tumor region. We aimed to improve magnetic hyperthermia of breast cancer by using innovative nanoparticles whi...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-015-0576-1

    authors: Kossatz S,Grandke J,Couleaud P,Latorre A,Aires A,Crosbie-Staunton K,Ludwig R,Dähring H,Ettelt V,Lazaro-Carrillo A,Calero M,Sader M,Courty J,Volkov Y,Prina-Mello A,Villanueva A,Somoza Á,Cortajarena AL,Miranda R,Hilge

    更新日期:2015-05-13 00:00:00

  • The diagnosis and management of pre-invasive breast disease: promise of new technologies in understanding pre-invasive breast lesions.

    abstract::Array-based comparative genomic hybridization, RNA expression profiling, and proteomic analyses are new molecular technologies used to study breast cancer. Invasive breast cancers were originally evaluated because they provided ample quantities of DNA, RNA, and protein. The application of these technologies to pre-inv...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr655

    authors: Jeffrey SS,Pollack JR

    更新日期:2003-01-01 00:00:00

  • RAD51C deletion screening identifies a recurrent gross deletion in breast cancer and ovarian cancer families.

    abstract::RAD51C is an integral part of the DNA double-strand repair through homologous recombination, and monoallelic mutations were found in ~1.3% of BRCA1/2-negative breast cancer (BC) and/or ovarian cancer (OC) families. Several studies confirmed the occurrence of RAD51C mutations predominantly in BC and/or OC families, alt...

    journal_title:Breast cancer research : BCR

    pub_type: 信件

    doi:10.1186/bcr3589

    authors: Schnurbein G,Hauke J,Wappenschmidt B,Weber-Lassalle N,Engert S,Hellebrand H,Garbes L,Becker A,Neidhardt G,Rhiem K,Meindl A,Schmutzler RK,Hahnen E

    更新日期:2013-12-20 00:00:00

  • A migrant study of pubertal timing and tempo in British-Bangladeshi girls at varying risk for breast cancer.

    abstract:INTRODUCTION:Earlier menarche is related to subsequent breast cancer risk, yet international differences in the age and tempo of other pubertal milestones and their relationships with body mass index (BMI) are not firmly established in populations at differing risk for breast cancer. We compared age and tempo of adrena...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-014-0469-8

    authors: Houghton LC,Cooper GD,Bentley GR,Booth M,Chowdhury OA,Troisi R,Ziegler RG,Hoover RN,Katki HA

    更新日期:2014-11-15 00:00:00

  • Dual inhibition of Type I and Type III PI3 kinases increases tumor cell apoptosis in HER2+ breast cancers.

    abstract:INTRODUCTION:Human epidermal growth factor receptor-2 (HER2) gene amplification (HER2+) drives tumor cell growth and survival in ~25% of breast cancers. HER2 signaling activates the type I phosphoinositide 3-kinase (PI3K), upon which these tumors rely. Consequently, inhibitors of HER2 and type I PI3K block growth and i...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-015-0656-2

    authors: Young CD,Arteaga CL,Cook RS

    更新日期:2015-12-04 00:00:00

  • The pathology of familial breast cancer: Morphological aspects.

    abstract::A small proportion of breast cancers are due to a heritable predisposition. Recently, two predisposition genes, BRCA1 and BRCA2, have been identified and cloned. The morphological features of tumours from patients harbouring mutations in the BRCA1 and BRCA2 genes differ from each other and from sporadic breast cancers...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr10

    authors: Lakhani SR

    更新日期:1999-01-01 00:00:00

  • Alternative splicing and the progesterone receptor in breast cancer.

    abstract::Progesterone receptor status is a marker for hormone responsiveness and disease prognosis in breast cancer. Progesterone receptor negative tumours have generally been shown to have a poorer prognosis than progesterone receptor positive tumours. The observed loss of progesterone receptor could be through a range of mec...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr2097

    authors: Cork DM,Lennard TW,Tyson-Capper AJ

    更新日期:2008-01-01 00:00:00

  • Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.

    abstract:INTRODUCTION:The status of tumor-infiltrating lymphocytes (TILs) has been recently proposed to predict clinical outcome of patients with breast cancer. We therefore studied the prognostic significance of CD8(+) TILs and FOXP3(+) TILs in residual tumors after neoadjuvant chemotherapy (NAC) and the alterations in these p...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,多中心研究

    doi:10.1186/s13058-015-0632-x

    authors: Miyashita M,Sasano H,Tamaki K,Hirakawa H,Takahashi Y,Nakagawa S,Watanabe G,Tada H,Suzuki A,Ohuchi N,Ishida T

    更新日期:2015-09-04 00:00:00

  • Does diet affect breast cancer risk?

    abstract::The role of specific dietary factors in breast cancer causation is not completely resolved. Results from prospective studies do not support the concept that fat intake in middle life has a major relation to breast cancer risk. However, weight gain in middle life contributes substantially to breast cancer risk. Alcohol...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr909

    authors: Holmes MD,Willett WC

    更新日期:2004-01-01 00:00:00

  • Nongenomic oestrogen signalling in oestrogen receptor negative breast cancer cells: a role for the angiotensin II receptor AT1.

    abstract:INTRODUCTION:Oestrogens can mediate some of their cell survival properties through a nongenomic mechanism that involves the mitogen-activated protein kinase (MAPK) pathway. The mechanism of this rapid signalling and its dependence on a membrane bound oestrogen receptor (ER), however, remains controversial. The role of ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr1509

    authors: Lim KT,Cosgrave N,Hill AD,Young LS

    更新日期:2006-01-01 00:00:00

  • CXCL17-derived CD11b+Gr-1+ myeloid-derived suppressor cells contribute to lung metastasis of breast cancer through platelet-derived growth factor-BB.

    abstract:BACKGROUND:Metastasis is the major cause of death from breast cancer. Colonization and adaption of metastatic cells in distant organs is a rate-limiting step of the cancer spreading. The underlying mechanisms responsible for the colonization of breast cancer to lung metastatic niches are not fully understood. METHODS:...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-019-1114-3

    authors: Hsu YL,Yen MC,Chang WA,Tsai PH,Pan YC,Liao SH,Kuo PL

    更新日期:2019-02-12 00:00:00

  • Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapatinib

    abstract:INTRODUCTION:Phosphatidylinositol 3-kinase (PI3K) pathway deregulation (that is PIK3CA mutations and/or phosphatase and tensin homolog (PTEN) loss) has been shown to enhance breast cancer cell survival and confer resistance to chemotherapeutic agents. We studied the prognostic and predictive value of PIK3CA mutations a...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-014-0405-y

    authors: Xu B,Guan Z,Shen Z,Tong Z,Jiang Z,Yang J,DeSilvio M,Russo M,Leigh M,Ellis C

    更新日期:2014-07-24 00:00:00

  • MiR-7 reduces the BCSC subset by inhibiting XIST to modulate the miR-92b/Slug/ESA axis and inhibit tumor growth.

    abstract:BACKGROUND:Breast cancer stem cells (BCSCs) are typically seed cells of breast tumor that initiate and maintain tumor growth. MiR-7, as a cancer inhibitor, decreases the BCSC subset and inhibits tumor progression through mechanisms that remain unknown. METHODS:We examined miR-7 expression in breast cancer and develope...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-020-01264-z

    authors: Li M,Pan M,You C,Zhao F,Wu D,Guo M,Xu H,Shi F,Zheng D,Dou J

    更新日期:2020-03-06 00:00:00

  • Involution of the mouse mammary gland is associated with an immune cascade and an acute-phase response, involving LBP, CD14 and STAT3.

    abstract:INTRODUCTION:Involution of the mammary gland is a complex process of controlled apoptosis and tissue remodelling. The aim of the project was to identify genes that are specifically involved in this process. METHODS:We used Affymetrix oligonucleotide microarrays to perform a detailed transcript analysis on the mechanis...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr753

    authors: Stein T,Morris JS,Davies CR,Weber-Hall SJ,Duffy MA,Heath VJ,Bell AK,Ferrier RK,Sandilands GP,Gusterson BA

    更新日期:2004-01-01 00:00:00

  • Antitumor activity of Cetuximab in combination with Ixabepilone on triple negative breast cancer stem cells.

    abstract:BACKGROUND:Developing novel strategies against treatment-resistant triple negative breast cancer (TNBC) cells remains a significant challenge. The ErbB family, including epidermal growth factor receptor (EGFR), plays key roles in metastasis, tumorigenesis, cell proliferation, and drug resistance. Recently, these charac...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-015-0662-4

    authors: Tanei T,Choi DS,Rodriguez AA,Liang DH,Dobrolecki L,Ghosh M,Landis MD,Chang JC

    更新日期:2016-01-12 00:00:00

  • Direct repression of MYB by ZEB1 suppresses proliferation and epithelial gene expression during epithelial-to-mesenchymal transition of breast cancer cells.

    abstract:INTRODUCTION:Epithelial-to-mesenchymal transition (EMT) promotes cell migration and is important in metastasis. Cellular proliferation is often downregulated during EMT, and the reverse transition (MET) in metastases appears to be required for restoration of proliferation in secondary tumors. We studied the interplay b...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr3580

    authors: Hugo HJ,Pereira L,Suryadinata R,Drabsch Y,Gonda TJ,Gunasinghe NP,Pinto C,Soo ET,van Denderen BJ,Hill P,Ramsay RG,Sarcevic B,Newgreen DF,Thompson EW

    更新日期:2013-11-27 00:00:00

  • Imprint of parity and age at first pregnancy on the genomic landscape of subsequent breast cancer.

    abstract:BACKGROUND:Although parity and age at first pregnancy are among the most known extrinsic factors that modulate breast cancer risk, their impact on the biology of subsequent breast cancer has never been explored in depth. Recent data suggest that pregnancy-induced tumor protection is different according to breast cancer...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-019-1111-6

    authors: Nguyen B,Venet D,Lambertini M,Desmedt C,Salgado R,Horlings HM,Rothé F,Sotiriou C

    更新日期:2019-02-15 00:00:00

  • Expression genomics in breast cancer research: microarrays at the crossroads of biology and medicine.

    abstract::Genome-wide expression microarray studies have revealed that the biological and clinical heterogeneity of breast cancer can be partly explained by information embedded within a complex but ordered transcriptional architecture. Comprising this architecture are gene expression networks, or signatures, reflecting biochem...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr1662

    authors: Miller LD,Liu ET

    更新日期:2007-01-01 00:00:00